Alemtuzumab Campath1H

Alemtuzumab is a humanized monoclonal antibody directed against the lymphocyte surface antigen CD52, which is abundantly expressed on normal and most malignant T lymphocytes.78 Alemtuzumab is currently the focus of many clinical trials in hematologic malignancies and has been used in the treatment of lymphomas and lymphoid leukemias. A published phase II trial of alemtuzumab in 22 patients with advanced MF/SS demonstrated a clinical response in 55% of the cases, with 32% complete remissions, including some SS patients clearing effectively circulating Sezary cells.79 Median response duration was 12 months, and ranged from 5 to 32 months. The compound is associated with significant hematologic toxicity and infectious complications consisting of reactivation of cytomegalovirus, herpes zoster, miliary tuberculosis, and pulmonary aspergillosis.

0 0

Post a comment